Designing and development of phthalimides as potent anti-tubulin hybrid molecules against malaria.
Antimalarial
Drug discovery
Drug resistance
Phthalimide analogs
Plasmodium falciparum
Tubulin
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Sep 2022
05 Sep 2022
Historique:
received:
13
10
2021
revised:
06
06
2022
accepted:
11
06
2022
pubmed:
25
6
2022
medline:
14
7
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Constant emergence of drug-resistant Plasmodium falciparum warrants urgent need for effective and inexpensive drugs. Herein, phthalimide (Pht) analogs possessing the bioactive scaffolds, benzimidazole and 1,2,3-triazole, were evaluated for in vitro and in vivo anti-plasmodial activity without any apparent hemolysis, or cytotoxicity. Analogs 4(a-e) inhibited the growth of 3D7 and RKL-9 strains at submicromolar concentrations. Defects were observed during parasite egress from or invasion of the red blood cells. Mitochondrial membrane depolarization was measured as one of the causes of cell death. Phts 4(a-e) in combination with artemisinin exhibited two-to three-fold increased efficacy. Biophysical and biochemical analysis suggest that Pht analogs mediate plasmodial growth inhibition by interacting with tubulin protein of the parasite. Lastly, Phts 4(a-e) significantly decreased parasitemia and extended host survival in murine model Plasmodium berghei ANKA infection. Combined, the data indicate that Pht analogs should be further explored, which could offer novel value to the antimalarial drug development pipeline.
Identifiants
pubmed: 35749989
pii: S0223-5234(22)00436-6
doi: 10.1016/j.ejmech.2022.114534
pii:
doi:
Substances chimiques
Antimalarials
0
Phthalimides
0
Tubulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114534Informations de copyright
Copyright © 2022. Published by Elsevier Masson SAS.